Aditxt (NASDAQ: ADTX) provides the AditxtScore(TM), a proprietary immune mapping technology designed to provide a personalized profile of the immune system. “Licensed from Stanford University, AditxtScore(TM) for COVID-19 is Aditxt’s first commercial product. It enables patients to know the level of protection that an immune response to the SARS-CoV-2 virus or vaccination confers them…The results may also influence the vaccine-hesitant populace to take the vaccine, particularly when it is determined that they are not protected by antibodies. Generally, the AditxtScore(TM) results offer information on whether an individual has antibodies that will protect them against the virus; if the antibodies are a result of vaccination or an immune response to a virus; whether the immune response is likely to protect against future infection; and the possible ways to minimize the risk of a future infection,” a recent article explains. Aditxt recently announced its latest authorized channel partner, Premier Medical Laboratory Services (“PMLS”), a leading advanced medical diagnostics lab. “As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status. With AditxtScore(TM), individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action for them,” said PMLS CEO Kevin Murdock of the partnership.
To view the full article, visit https://ibn.fm/yrYcS
About Aditxt Inc.
Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork